You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameConjugated Equine Estrogens
Accession NumberDB00286  (APRD00396)
TypeSmall Molecule
GroupsApproved
Description

Conjugated Equine Estrogens (CEEs) are composed of a mixture of the water-soluble salts of sulfate esters from estrone, equilin, 17 α-dihydroequilin, and other related steroids that are purified from pregnant horse urine. Available as the product Premarin (FDA), this combination of equine-derived estrogenic compounds is indicated for the following conditions: treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy associated with menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; palliation of metastatic breast cancer; palliation of advanced androgen-dependent carcinoma of the prostate; and for prevention of postmenopausal osteoporosis.

All estrogen products mimic the effects of endogenous estrogens in the body which are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control. This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal dryness, and vulvovaginal atrophy. These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as Hormone Replacement Therapy (HRT).

Pharmacologic estrogen products are available in a variety of formats. Although many of them contain several compounds in common (such as the estrogen derivatives sodium estrone sulfate and sodium equilin sulfate), they vary by their original source (such as horse-, human-, or plant-derived), and the remaining mixture of estrogenic derivatives. Conjugated Equine Estrogens (CEEs) are derived from the urine of pregnant mares and contain a blend of at least 10 estrogen derivatives. Marketed under the brand name Premarin, CEEs are the most frequently used form of conjugated estrogens. There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time. Conjugated estrogens are also available in a plant-derived synthetic form that replicates the naturally occurring, horse-derived forms. Available as either “Synthetic Conjugated Estrogens, A” containing 9 estrogen derivatives (available as Cenestin) or as “Synthetic Conjugated Estrogens, B” containing 10 estrogen derivatives (available as Enjuvia), these products are isolated as precursors from yam or soy plants and then chemically modified to mimic the products available in their naturally occurring form.

Structure
Thumb
Synonyms
conjugated estrogens
Estrogens, Conjugated
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
C.E.S. Tabletstablet1.25 mgoralValeant Canada Lp Valeant Canada S.E.C.1963-12-312014-07-30Canada
C.E.S. Tabletstablet0.9 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-03-142014-07-30Canada
C.E.S. Tabletstablet0.625 mgoralValeant Canada Lp Valeant Canada S.E.C.1963-12-31Not applicableCanada
C.E.S. Tabletstablet0.3 mgoralValeant Canada Lp Valeant Canada S.E.C.1997-03-142014-07-30Canada
Congest Tab 0.3mgtablet0.3 mgoralLaboratoires Trianon Inc1990-12-31Not applicableCanada
Congest Tab 0.625mgtablet0.625 mgoralLaboratoires Trianon Inc1990-12-31Not applicableCanada
Congest Tab 0.9mgtablet0.9 mgoralLaboratoires Trianon Inc1990-12-31Not applicableCanada
Congest Tab 1.25mgtablet1.25 mgoralLaboratoires Trianon Inc1990-12-31Not applicableCanada
Congest Tab 2.5mgtablet2.5 mgoralLaboratoires Trianon Inc1990-12-31Not applicableCanada
PMS-conjugated Estrogens C.S.D.tablet1.25 mgoralPharmascience Inc1983-12-31Not applicableCanada
PMS-conjugated Estrogens C.S.D.tablet0.625 mgoralPharmascience Inc1983-12-31Not applicableCanada
PMS-conjugated Estrogens C.S.D.tablet0.9 mgoralPharmascience Inc1999-03-03Not applicableCanada
PMS-conjugated Estrogens C.S.D.tablet0.3 mgoralPharmascience Inc1999-03-03Not applicableCanada
Premarintablet, film coated.625 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-21Not applicableUs
Premarintablet, film coated.625 mg/1oralA S Medication Solutions Llc2006-01-01Not applicableUs
Premarininjection, powder, lyophilized, for solution25 mg/5mLintramuscular; intravenousWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.1956-12-01Not applicableUs
Premarintablet, film coated.45 mg/1oralCardinal Health2006-01-01Not applicableUs
Premarintablet, film coated1.25 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2004-09-01Not applicableUs
Premarintablet, film coated.625 mg/1oralAphena Pharma Solutions Tennessee, Inc.2006-01-01Not applicableUs
Premarintablet, film coated.9 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2006-01-01Not applicableUs
Premarintablet, film coated.3 mg/1oralCardinal Health2006-01-01Not applicableUs
Premarintablet (extended-release)1.25 mgoralPfizer Canada Inc2014-10-03Not applicableCanada
Premarintablet, film coated.3 mg/1oralAphena Pharma Solutions Tennessee, Inc.2006-01-01Not applicableUs
Premarintablet, film coated.625 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2006-01-01Not applicableUs
Premarintablet, film coated.625 mg/1oralCardinal Health2006-01-01Not applicableUs
Premarintablet (extended-release)0.625 mgoralPfizer Canada Inc2014-10-03Not applicableCanada
Premarintablet, film coated1.25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-22Not applicableUs
Premarintablet, film coated.3 mg/1oralPhysicians Total Care, Inc.2004-11-16Not applicableUs
Premarintablet, film coated.45 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2006-01-01Not applicableUs
Premarintablet (extended-release)0.3 mgoralPfizer Canada Inc2014-10-03Not applicableCanada
Premarintablet, film coated.45 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-22Not applicableUs
Premarintablet1.25 mgoralPfizer Canada Inc1994-12-31Not applicableCanada
Premarintablet, film coated.625 mg/1oralPhysicians Total Care, Inc.2005-02-08Not applicableUs
Premarintablet, film coated.3 mg/1oralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2006-01-01Not applicableUs
Premarintablet, film coated.3 mg/1oralA S Medication Solutions2006-01-01Not applicableUs
Premarintablet, film coated.9 mg/1oralAvera Mc Kennan Hospital2015-08-03Not applicableUs
Premarintablet, film coated.9 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-22Not applicableUs
Premarintablet0.3 mgoralPfizer Canada Inc1994-12-31Not applicableCanada
Premarintablet, film coated.625 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Premarintablet0.625 mgoralPfizer Canada Inc1994-12-31Not applicableCanada
Premarintablet, film coated1.25 mg/1oralA S Medication Solutions Llc2004-09-01Not applicableUs
Premarintablet, film coated.9 mg/1oralCardinal Health2006-01-01Not applicableUs
Premarintablet, film coated.3 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-22Not applicableUs
Premarin Crm 0.625mg/gmcream.625 mgtopical; vaginalAyerst Laboratories1951-12-311996-09-10Canada
Premarin Inj 25mg/5mlpowder for solution25 mgintramuscular; intravenousAyerst Laboratories1953-12-311996-09-10Canada
Premarin Intravenouspowder for solution25 mgintramuscular; intravenousPfizer Canada Inc1994-12-31Not applicableCanada
Premarin Tablets 0.3mgtablet0.3 mgoralAyerst Laboratories1951-12-311996-09-10Canada
Premarin Tablets 0.625mgtablet0.625 mgoralAyerst Laboratories1951-12-311996-09-10Canada
Premarin Tablets 0.9mgtablet0.9 mgoralWyeth Canada1993-12-312007-08-13Canada
Premarin Tablets 1.25mgtablet1.25 mgoralAyerst Laboratories1951-12-311996-09-10Canada
Premarin Tablets 2.5mgtablet2.5 mgoralWyeth Ayerst Canada Inc.1996-09-202000-08-02Canada
Premarin Tablets 2.5mgtablet2.5 mgoralAyerst Laboratories1951-12-311997-08-15Canada
Premarin Vaginalcream.625 mg/gvaginalWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.1978-11-01Not applicableUs
Premarin Vaginal Creamcream0.625 mgtopical; vaginalPfizer Canada Inc1994-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-conest Tab 0.3mgtablet0.3 mgoralApotex Inc1994-12-312009-10-09Canada
Apo-conest Tab 0.625mgtablet0.625 mgoralApotex Inc1994-12-312009-10-09Canada
Apo-conest Tab 0.9mgtablet0.9 mgoralApotex Inc1994-12-312009-10-09Canada
Apo-conest Tab 1.25mgtablet1.25 mgoralApotex Inc1994-12-312009-10-09Canada
Apo-conest Tab 2.5mgtablet2.5 mgoralApotex Inc1994-12-312009-10-09Canada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
DuaveeWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
DuavivePfizer Canada Inc
Esterified Estrogens and MethyltestosteroneSeton Pharmaceuticals
PremphaseWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
PremplusPfizer Canada Inc
Premplus CyclePfizer Canada Inc
PremproWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
SaltsNot Available
Categories
UNII6K6FDA543A
CAS number438-67-5
WeightAverage: 372.411
Monoisotopic: 372.100739147
Chemical FormulaC18H21NaO5S
InChI KeyInChIKey=VUCAHVBMSFIGAI-ZFINNJDLSA-M
InChI
InChI=1S/C18H22O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14-,15-,16+,18+;/m1./s1
IUPAC Name
sodium (1S,10R,11S,15S)-15-methyl-14-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-trien-5-yl sulfate
SMILES
[Na+].[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OS([O-])(=O)=O)C=C3CC[C@@]21[H]
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfated steroids. These are sterol lipids containing a sulfate group attached to the steroid skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSulfated steroids
Direct ParentSulfated steroids
Alternative Parents
Substituents
  • Sulfated steroid
  • 3-sulfated steroid
  • Sulfated steroid skeleton
  • Oxosteroid
  • 17-oxosteroid
  • Estrane-skeleton
  • Phenanthrene
  • Tetralin
  • Sulfuric acid monoester
  • Benzenoid
  • Sulfuric acid ester
  • Sulfate-ester
  • Organic sulfuric acid or derivatives
  • Ketone
  • Hydrocarbon derivative
  • Organic alkali metal salt
  • Organic sodium salt
  • Organic salt
  • Organooxygen compound
  • Carbonyl group
  • Organic zwitterion
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationConjugated Equine Estrogens (CEEs) are indicated for the following conditions: treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy associated with menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; palliation of metastatic breast cancer; palliation of advanced androgen-dependent carcinoma of the prostate; and for prevention of postmenopausal osteoporosis.
PharmacodynamicsNot Available
Mechanism of actionAll estrogen products mimic the effects of endogenous estrogens in the body which are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control. This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal dryness, and vulvovaginal atrophy. These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as Hormone Replacement Therapy (HRT).
Related Articles
AbsorptionConjugated estrogens are water-soluble and are well-absorbed from the gastrointestinal tract after release from the drug formulation. Tablets release conjugated estrogens slowly over several hours.
Volume of distribution

The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentration in the sex hormone target organs.

Protein bindingEstrogens circulate in the blood largely bound to sex hormone-binding globulin (SHBG) and albumin.
Metabolism

Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4).

Route of eliminationEstradiol, estrone, and estriol are excreted in the urine, along with glucuronide and sulfate conjugates. Exogenous estrogens are metabolized in the same manner as endogenous estrogens.
Half lifeFollowing a dose of 0.625 mg of conjugated estrogens, the half life of estrone, baseline-adjusted estrone, and equilin was found to be 26.7 hr, 14.8 hr, and 11.4 hr, respectively.
ClearanceNot Available
ToxicityNausea and vomiting
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.997
Blood Brain Barrier+0.9486
Caco-2 permeable-0.8738
P-glycoprotein substrateNon-substrate0.5295
P-glycoprotein inhibitor INon-inhibitor0.5198
P-glycoprotein inhibitor IINon-inhibitor0.9431
Renal organic cation transporterNon-inhibitor0.8313
CYP450 2C9 substrateNon-substrate0.7886
CYP450 2D6 substrateNon-substrate0.8125
CYP450 3A4 substrateSubstrate0.6454
CYP450 1A2 substrateNon-inhibitor0.8152
CYP450 2C9 inhibitorNon-inhibitor0.8454
CYP450 2D6 inhibitorNon-inhibitor0.9026
CYP450 2C19 inhibitorNon-inhibitor0.8017
CYP450 3A4 inhibitorNon-inhibitor0.9204
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8461
Ames testNon AMES toxic0.5177
CarcinogenicityNon-carcinogens0.5338
BiodegradationNot ready biodegradable0.6303
Rat acute toxicity2.3418 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6053
hERG inhibition (predictor II)Inhibitor0.7941
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wyeth pharmaceuticals inc
  • Duramed research inc
  • Teva womens health inc
  • Roche palo alto llc
Packagers
Dosage forms
FormRouteStrength
Tabletoral0.3 mg
Tabletoral0.625 mg
Tabletoral0.9 mg
Tabletoral1.25 mg
Tabletoral2.5 mg
Tablet, film coatedoral
Tablet (immediate and extended release)oral
Tabletoral
Injection, powder, lyophilized, for solutionintramuscular; intravenous25 mg/5mL
Tablet (extended-release)oral0.3 mg
Tablet (extended-release)oral0.625 mg
Tablet (extended-release)oral1.25 mg
Tablet, film coatedoral.3 mg/1
Tablet, film coatedoral.45 mg/1
Tablet, film coatedoral.625 mg/1
Tablet, film coatedoral.9 mg/1
Tablet, film coatedoral1.25 mg/1
Creamtopical; vaginal.625 mg
Powder for solutionintramuscular; intravenous25 mg
Creamvaginal.625 mg/g
Creamtopical; vaginal0.625 mg
Kit
Kit; tabletoral
Tablet, sugar coatedoral
Prices
Unit descriptionCostUnit
Premarin 0.625 mg/gm Cream 42.5 gm Tube134.05USD tube
Premarin 25 mg vial107.54USD vial
Premphase 28 0.625-5 mg tablet Disp Pack69.99USD disp
Premarin vaginal cream-appl3.07USD g
Prempro 0.3 mg-1.5 mg tablet2.34USD tablet
Prempro 0.45-1.5 mg tablet2.34USD tablet
Prempro 0.625-2.5 mg tablet2.34USD tablet
Prempro 0.625-5 mg tablet2.34USD tablet
Premarin 0.45 mg tablet1.97USD tablet
Premarin 0.9 mg tablet1.97USD tablet
Premarin 2.5 mg tablet1.83USD tablet
Premarin 2.5 mg Tabs1.82USD tablet
Premarin 0.3 mg tablet1.42USD tablet
Premarin 0.625 mg tablet1.42USD tablet
Premarin 1.25 mg tablet1.42USD tablet
Premarin 0.625 mg/g Cream0.69USD g
C.E.S. 0.625 mg Tablet0.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5547948 No1995-01-172015-01-17Us
US5908638 No1995-07-262015-07-26Us
US5998402 No1997-04-042017-04-04Us
US6479535 No1999-05-062019-05-06Us
US7138392 No1997-04-042017-04-04Us
US7683051 No2007-03-102027-03-10Us
US8815934 No1999-05-062019-05-06Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point173 °CNot Available
water solubility0.0036 mg/mlNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0045 mg/mLALOGPS
logP2.75ALOGPS
logP3.83ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)-1.7ChemAxon
pKa (Strongest Basic)-7.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area83.5 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity87.95 m3·mol-1ChemAxon
Polarizability36.47 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Vallapa Soong, “Process for the preparation of conjugated estrogens from pregnant mare urine.” U.S. Patent US20020156303, issued October 24, 2002.

US20020156303
General References
  1. 14. (2015). In Pharmacology for Women’s Health. Jones & Bartlett Publishers.
External Links
ATC CodesG03CC07G03CA57
AHFS Codes
  • 68:16.04
PDB EntriesNot Available
FDA labelDownload (5.44 MB)
MSDSDownload (34.7 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Conjugated Equine Estrogens.
AbciximabConjugated Equine Estrogens may decrease the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Abiraterone.
AcenocoumarolConjugated Equine Estrogens may decrease the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Acetaminophen.
AfatinibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Conjugated Equine Estrogens.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Conjugated Equine Estrogens.
AldosteroneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Alfentanil.
AmantadineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Amantadine.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Conjugated Equine Estrogens.
Aminohippuric acidThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Aminohippuric acid.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Conjugated Equine Estrogens.
AmiodaroneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Amsacrine.
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Conjugated Equine Estrogens.
AncrodConjugated Equine Estrogens may decrease the anticoagulant activities of Ancrod.
Anthrax immune globulin humanConjugated Equine Estrogens may increase the thrombogenic activities of Anthrax immune globulin human.
Antithrombin III humanConjugated Equine Estrogens may decrease the anticoagulant activities of Antithrombin III human.
ApixabanConjugated Equine Estrogens may decrease the anticoagulant activities of Apixaban.
AprepitantThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Aprepitant.
ArdeparinConjugated Equine Estrogens may decrease the anticoagulant activities of Ardeparin.
ArgatrobanConjugated Equine Estrogens may decrease the anticoagulant activities of Argatroban.
AstemizoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Azithromycin.
BecaplerminConjugated Equine Estrogens may decrease the anticoagulant activities of Becaplermin.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Conjugated Equine Estrogens.
BenzocaineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Conjugated Equine Estrogens.
BexaroteneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Biperiden.
BivalirudinConjugated Equine Estrogens may decrease the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Bromocriptine.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Conjugated Equine Estrogens.
BuprenorphineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Buspirone.
C1 Esterase Inhibitor (Human)Conjugated Equine Estrogens may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).
C1 Esterase Inhibitor (Recombinant)Conjugated Equine Estrogens may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).
CabazitaxelThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Carbamazepine.
CarvedilolThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ceritinib.
CertoparinConjugated Equine Estrogens may decrease the anticoagulant activities of Certoparin.
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Conjugated Equine Estrogens.
ChloroquineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Conjugated Equine Estrogens.
CilazaprilThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Citalopram.
Citric AcidConjugated Equine Estrogens may decrease the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Clemastine.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Conjugated Equine Estrogens.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Conjugated Equine Estrogens.
ClofazimineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Clomipramine.
ClotrimazoleThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Conivaptan.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Conjugated Equine Estrogens.
CrizotinibThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Crizotinib.
CyclophosphamideThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateConjugated Equine Estrogens may decrease the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Dactinomycin.
DalteparinConjugated Equine Estrogens may decrease the anticoagulant activities of Dalteparin.
DanaparoidConjugated Equine Estrogens may decrease the anticoagulant activities of Danaparoid.
DarunavirThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Conjugated Equine Estrogens.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Conjugated Equine Estrogens.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Conjugated Equine Estrogens.
DelavirdineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Desipramine.
DesirudinConjugated Equine Estrogens may decrease the anticoagulant activities of Desirudin.
DesloratadineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Desloratadine.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Conjugated Equine Estrogens.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Conjugated Equine Estrogens.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Conjugated Equine Estrogens.
DexamethasoneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Conjugated Equine Estrogens.
DextranConjugated Equine Estrogens may decrease the anticoagulant activities of Dextran.
Dextran 40Conjugated Equine Estrogens may decrease the anticoagulant activities of Dextran 40.
Dextran 70Conjugated Equine Estrogens may decrease the anticoagulant activities of Dextran 70.
Dextran 75Conjugated Equine Estrogens may decrease the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Diclofenac.
DicoumarolConjugated Equine Estrogens may decrease the anticoagulant activities of Dicoumarol.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Conjugated Equine Estrogens.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Conjugated Equine Estrogens.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Conjugated Equine Estrogens.
DigoxinThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Diltiazem.
DipyridamoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Dipyridamole.
DoxazosinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Dronedarone.
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Conjugated Equine Estrogens.
Edetic AcidConjugated Equine Estrogens may decrease the anticoagulant activities of Edetic Acid.
EdoxabanConjugated Equine Estrogens may decrease the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Elbasvir.
EltrombopagThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Eltrombopag.
EnalaprilThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Enalapril.
EnoxaparinConjugated Equine Estrogens may decrease the anticoagulant activities of Enoxaparin.
EntacaponeThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Entacapone.
EnzalutamideThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Enzalutamide.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Conjugated Equine Estrogens.
EquilinThe serum concentration of Equilin can be increased when it is combined with Conjugated Equine Estrogens.
ErgonovineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Eslicarbazepine acetate.
EstramustineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Estrone can be increased when it is combined with Conjugated Equine Estrogens.
EstroneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Estrone.
Ethyl biscoumacetateConjugated Equine Estrogens may decrease the anticoagulant activities of Ethyl biscoumacetate.
EtoposideThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Etravirine.
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Conjugated Equine Estrogens.
FelodipineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fidaxomicin.
FluconazoleThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Conjugated Equine Estrogens.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Conjugated Equine Estrogens.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Conjugated Equine Estrogens.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Conjugated Equine Estrogens.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Conjugated Equine Estrogens.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Conjugated Equine Estrogens.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Conjugated Equine Estrogens.
FluoxetineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fluphenazine.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Conjugated Equine Estrogens.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Conjugated Equine Estrogens.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Conjugated Equine Estrogens.
FlurazepamThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Conjugated Equine Estrogens.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Conjugated Equine Estrogens.
FluvoxamineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumConjugated Equine Estrogens may decrease the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Conjugated Equine Estrogens can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Haloperidol.
HeparinConjugated Equine Estrogens may decrease the anticoagulant activities of Heparin.
HirulogConjugated Equine Estrogens may decrease the anticoagulant activities of Hirulog.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Conjugated Equine Estrogens.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Conjugated Equine Estrogens.
IdelalisibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Imipramine.
IndinavirThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Indomethacin.
IsavuconazoniumThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Lapatinib.
LenalidomideConjugated Equine Estrogens may increase the thrombogenic activities of Lenalidomide.
LepirudinConjugated Equine Estrogens may decrease the anticoagulant activities of Lepirudin.
LevofloxacinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Levofloxacin.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Conjugated Equine Estrogens.
LevothyroxineThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Lidocaine.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Conjugated Equine Estrogens.
LiothyronineThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Liothyronine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Conjugated Equine Estrogens.
LiotrixThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Losartan.
LovastatinThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Lumacaftor.
MaprotilineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Mebendazole.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Conjugated Equine Estrogens.
MefloquineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Megestrol acetate.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Conjugated Equine Estrogens.
MeprobamateThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Meprobamate.
MethadoneThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Methadone.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Conjugated Equine Estrogens.
MetoprololThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Metoprolol.
MexiletineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Mexiletine.
MibefradilThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Midazolam.
MifepristoneThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Mifepristone.
MitomycinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Modafinil.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Conjugated Equine Estrogens.
MorphineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Morphine.
NadroparinConjugated Equine Estrogens may decrease the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Nilotinib.
NisoldipineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Norethisterone.
OlaparibThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Olaparib.
OmeprazoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Osimertinib.
OspemifeneThe risk or severity of adverse effects can be increased when Conjugated Equine Estrogens is combined with Ospemifene.
OtamixabanConjugated Equine Estrogens may decrease the anticoagulant activities of Otamixaban.
P-NitrophenolThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Pantoprazole.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Conjugated Equine Estrogens.
ParoxetineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe metabolism of Conjugated Equine Estrogens can be increased when combined with Pentobarbital.
Pentosan PolysulfateConjugated Equine Estrogens may decrease the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Perindopril.
PhenindioneConjugated Equine Estrogens may decrease the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Phenobarbital.
PhenprocoumonConjugated Equine Estrogens may decrease the anticoagulant activities of Phenprocoumon.
PhenytoinThe metabolism of Conjugated Equine Estrogens can be increased when combined with Phenytoin.
PimozideThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Pimozide.
Platelet Activating FactorThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Prazosin.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Conjugated Equine Estrogens.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Conjugated Equine Estrogens.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Conjugated Equine Estrogens.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Conjugated Equine Estrogens.
PrimidoneThe metabolism of Conjugated Equine Estrogens can be increased when combined with Primidone.
ProbenecidThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Propranolol.
Protein CConjugated Equine Estrogens may decrease the anticoagulant activities of Protein C.
ProtocatechualdehydeConjugated Equine Estrogens may decrease the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Protriptyline.
QuercetinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Quinine.
RanitidineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Reserpine.
ReviparinConjugated Equine Estrogens may decrease the anticoagulant activities of Reviparin.
RifabutinThe metabolism of Conjugated Equine Estrogens can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Conjugated Equine Estrogens can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Rilpivirine.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Conjugated Equine Estrogens.
RitonavirThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Ritonavir.
RivaroxabanConjugated Equine Estrogens may decrease the anticoagulant activities of Rivaroxaban.
RolapitantThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Rolapitant.
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Conjugated Equine Estrogens.
RopiniroleThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Ropinirole.
SaquinavirThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Sirolimus.
Somatropin recombinantThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Conjugated Equine Estrogens.
SorafenibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Sulfisoxazole.
SulodexideConjugated Equine Estrogens may decrease the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Taurocholic Acid.
TelaprevirThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Testosterone.
Testosterone PropionateThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Testosterone Propionate.
ThalidomideConjugated Equine Estrogens may increase the thrombogenic activities of Thalidomide.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Conjugated Equine Estrogens.
TheophyllineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Theophylline.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Conjugated Equine Estrogens.
TicagrelorThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Ticlopidine.
TipranavirConjugated Equine Estrogens may increase the dermatologic adverse activities of Tipranavir.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Conjugated Equine Estrogens.
TocilizumabThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Tocilizumab.
TolcaponeThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Tolcapone.
TolvaptanThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Tolvaptan.
TrazodoneThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Trazodone.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Conjugated Equine Estrogens.
TrifluoperazineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Troleandomycin.
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Conjugated Equine Estrogens.
VemurafenibThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Verapamil.
VinblastineThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Vinorelbine.
Vitamin CThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Vitamin C.
VoriconazoleThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Voriconazole.
WarfarinConjugated Equine Estrogens may decrease the anticoagulant activities of Warfarin.
XimelagatranConjugated Equine Estrogens may decrease the anticoagulant activities of Ximelagatran.
ZimelidineThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Ropero AB, Eghbali M, Minosyan TY, Tang G, Toro L, Stefani E: Heart estrogen receptor alpha: distinct membrane and nuclear distribution patterns and regulation by estrogen. J Mol Cell Cardiol. 2006 Sep;41(3):496-510. Epub 2006 Jul 28. [PubMed:16876190 ]
  2. Stroud FC, Appt SE, Wilson ME, Franke AA, Adams MR, Kaplan JR: Concentrations of isoflavones in macaques consuming standard laboratory monkey diet. J Am Assoc Lab Anim Sci. 2006 Jul;45(4):20-3. [PubMed:16884174 ]
  3. Hou NN, Zhu YM, Huang HF: [The expression of estrogen receptor alpha and beta in the intervention of different estrogens in rat bone metabolism]. Fen Zi Xi Bao Sheng Wu Xue Bao. 2006 Aug;39(4):289-96. [PubMed:16955786 ]
  4. Gouva L, Tsatsoulis A: The role of estrogens in cardiovascular disease in the aftermath of clinical trials. Hormones (Athens). 2004 Jul-Sep;3(3):171-83. [PubMed:16982590 ]
  5. Smith MR: Selective estrogen receptor modulators to prevent treatment-related osteoporosis. Rev Urol. 2005;7 Suppl 3:S30-5. [PubMed:16985877 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. [PubMed:12865317 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Zhu BT, Wu KY, Wang P, Cai MX, Conney AH: O-methylation of catechol estrogens by human placental catechol-o-methyltransferase: interindividual differences in sensitivity to heat inactivation and to inhibition by dietary polyphenols. Drug Metab Dispos. 2010 Oct;38(10):1892-9. doi: 10.1124/dmd.110.033548. Epub 2010 Jul 6. [PubMed:20606002 ]
  2. Jobe SO, Ramadoss J, Koch JM, Jiang Y, Zheng J, Magness RR: Estradiol-17beta and its cytochrome P450- and catechol-O-methyltransferase-derived metabolites stimulate proliferation in uterine artery endothelial cells: role of estrogen receptor-alpha versus estrogen receptor-beta. Hypertension. 2010 Apr;55(4):1005-11. doi: 10.1161/HYPERTENSIONAHA.109.146399. Epub 2010 Mar 8. [PubMed:20212268 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Hirohashi T, Suzuki H, Sugiyama Y: Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem. 1999 May 21;274(21):15181-5. [PubMed:10329726 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Zelcer N, Reid G, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, Borst P: Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7. [PubMed:12523936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Qian YM, Song WC, Cui H, Cole SP, Deeley RG: Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. J Biol Chem. 2001 Mar 2;276(9):6404-11. Epub 2000 Dec 1. [PubMed:11102445 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ: Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther. 2000 Jul;294(1):73-9. [PubMed:10871297 ]
  2. Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, Beuers U, Paumgartner G: Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. FEBS Lett. 1998 Mar 13;424(3):173-6. [PubMed:9539145 ]
  3. Kanai N, Lu R, Bao Y, Wolkoff AW, Vore M, Schuster VL: Estradiol 17 beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter. Am J Physiol. 1996 Feb;270(2 Pt 2):F326-31. [PubMed:8779894 ]
  4. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
  5. Kontaxi M, Echkardt U, Hagenbuch B, Stieger B, Meier PJ, Petzinger E: Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide. J Pharmacol Exp Ther. 1996 Dec;279(3):1507-13. [PubMed:8968376 ]
  6. Pang KS, Wang PJ, Chung AY, Wolkoff AW: The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6. [PubMed:9794920 ]
  7. Bossuyt X, Muller M, Meier PJ: Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J Hepatol. 1996 Nov;25(5):733-8. [PubMed:8938553 ]
  8. Hagenbuch B, Adler ID, Schmid TE: Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20. [PubMed:10600646 ]
  9. Lee TK, Koh AS, Cui Z, Pierce RH, Ballatori N: N-glycosylation controls functional activity of Oatp1, an organic anion transporter. Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G371-81. Epub 2003 Apr 17. [PubMed:12702494 ]
  10. Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y: Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther. 1999 Feb;288(2):627-34. [PubMed:9918568 ]
  11. Eckhardt U, Schroeder A, Stieger B, Hochli M, Landmann L, Tynes R, Meier PJ, Hagenbuch B: Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am J Physiol. 1999 Apr;276(4 Pt 1):G1037-42. [PubMed:10198348 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. [PubMed:9486191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Not Available
Gene Name:
SLC22A10
Uniprot ID:
Q63ZE4
Molecular Weight:
60256.57 Da
References
  1. Youngblood GL, Sweet DH: Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney. Am J Physiol Renal Physiol. 2004 Aug;287(2):F236-44. Epub 2004 Apr 6. [PubMed:15068970 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099 ]
  2. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T: Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003 Apr;23(4):432-40. [PubMed:12679720 ]
  3. Nagata Y, Kusuhara H, Endou H, Sugiyama Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002 May;61(5):982-8. [PubMed:11961115 ]
  4. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  5. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK: Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem. 2002 Jul 26;277(30):26934-43. Epub 2002 May 13. [PubMed:12011098 ]
  6. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168 ]
  7. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:
SLCO1C1
Uniprot ID:
Q9NYB5
Molecular Weight:
78695.625 Da
References
  1. Tohyama K, Kusuhara H, Sugiyama Y: Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology. 2004 Sep;145(9):4384-91. Epub 2004 May 27. [PubMed:15166123 ]
  2. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. [PubMed:12351693 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A: Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9. [PubMed:11683238 ]
  2. Nozawa T, Tamai I, Sai Y, Nezu J, Tsuji A: Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol. 2003 Jul;55(7):1013-20. [PubMed:12906759 ]
  3. Cui Y, Konig J, Leier I, Buchholz U, Keppler D: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30. Epub 2000 Dec 27. [PubMed:11134001 ]
  4. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46. Epub 2004 May 24. [PubMed:15159445 ]
  5. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I: Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos. 2004 Mar;32(3):291-4. [PubMed:14977862 ]
  6. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
  7. van Montfoort JE, Schmid TE, Adler ID, Meier PJ, Hagenbuch B: Functional characterization of the mouse organic-anion-transporting polypeptide 2. Biochim Biophys Acta. 2002 Aug 19;1564(1):183-8. [PubMed:12101011 ]
  8. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
  2. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A: Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9. [PubMed:11683238 ]
  3. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PubMed:12724351 ]
  4. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227 ]
  5. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23. Epub 2005 Jan 7. [PubMed:15640378 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK: Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem. 2002 Jul 26;277(30):26934-43. Epub 2002 May 13. [PubMed:12011098 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efficiently transports the major species of bile acids.
Gene Name:
SLC51A
Uniprot ID:
Q86UW1
Molecular Weight:
37734.575 Da
References
  1. Seward DJ, Koh AS, Boyer JL, Ballatori N: Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. Epub 2003 Apr 28. [PubMed:12719432 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efficiently transports the major species of bile acids. Modulates SLC51A glycosylation, membrane trafficking and stability activities.
Gene Name:
SLC51B
Uniprot ID:
Q86UW2
Molecular Weight:
14346.195 Da
References
  1. Seward DJ, Koh AS, Boyer JL, Ballatori N: Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. Epub 2003 Apr 28. [PubMed:12719432 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Spears KJ, Ross J, Stenhouse A, Ward CJ, Goh LB, Wolf CR, Morgan P, Ayrton A, Friedberg TH: Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol. 2005 Feb 1;69(3):415-23. Epub 2004 Dec 22. [PubMed:15652233 ]
  2. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as the thyroid hormones T3 (triiodo-L-thyronine), T4 (thyroxine) and rT3, and of estrone-3-sulfate and taurocholate.
Gene Name:
SLCO4A1
Uniprot ID:
Q96BD0
Molecular Weight:
77192.505 Da
References
  1. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60. [PubMed:10873595 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Purine nucleotide transmembrane transporter activity
Specific Function:
Participates in physiological processes involving bile acids, conjugated steroids and cyclic nucleotides. Enhances the cellular extrusion of cAMP and cGMP. Stimulates the ATP-dependent uptake of a range of physiological and synthetic lipophilic anions, including the glutathione S-conjugates leukotriene C4 and dinitrophenyl S-glutathione, steroid sulfates such as dehydroepiandrosterone 3-sulfate...
Gene Name:
ABCC11
Uniprot ID:
Q96J66
Molecular Weight:
154299.625 Da
References
  1. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD: Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005 Feb;67(2):545-57. Epub 2004 Nov 10. [PubMed:15537867 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Cui Y, Konig J, Leier I, Buchholz U, Keppler D: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30. Epub 2000 Dec 27. [PubMed:11134001 ]
  2. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
  3. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46. Epub 2004 May 24. [PubMed:15159445 ]
  4. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I: Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos. 2004 Mar;32(3):291-4. [PubMed:14977862 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate (PubMed:10873595). Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 and vasopressin, but not DPDPE (a derivative of enkephalin lacking an N-terminal tyrosine residue), estrone-3-sulfate, taurocholate, digoxin nor DHEAS (PubMed:16971491).
Gene Name:
SLCO3A1
Uniprot ID:
Q9UIG8
Molecular Weight:
76552.135 Da
References
  1. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60. [PubMed:10873595 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
  2. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043 ]
  3. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. [PubMed:12920197 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 30, 2016 02:13